Newsstand | Page 9 | Aplastic Anemia & MDS International Foundation


Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome

Originally Published: 04/02/2018
Background DNMT3A gene mutation has been associated with poor prognosis in acute myeloid leukemia, but its clinical implications in myelodysplastic syndrome (MDS) and dynamic changes during disease progression remain controversial.   

Minimal Residual Disease May Predict AML Relapse, Death

Originally Published: 03/29/2018
Targeted sequencing-based detection of molecular minimal residual disease during complete remission was associated with an increased risk of relapse or death in patients with acute myeloid leukemia (AML), according to Dutch researchers.

New Options for Acute Myeloid Leukemia

Originally Published: 03/29/2018
Four new treatments for patients with acute myeloid leukemia (AML) were approved in 2017, including some first-in-class drugs with novel mechanisms of action, which offer better outcomes for select patients.

The Science of Eating Well: MSK Research Focuses on Nutrition after a Stem Cell Transplant

Originally Published: 03/29/2018
MSK researchers have shown the crucial role that a healthy diet plays in cancer recovery. They are now developing unique ways to help people who are having transplants maintain good nutrition.

Firstline Eltrombopag Receives Breakthrough Designation for Severe Aplastic Anemia

Originally Published: 03/01/2018
The FDA granted breakthrough-therapy designation for firstline eltrombopag to treat severe aplastic anemia (SAA).

MDS Update - January 2018

Originally Published: 02/26/2018

Scientists Discover a Bone-Deep Risk for Heart Disease

Originally Published: 02/01/2018
Few doctors, and even fewer patients, have heard of CHIP. But it is emerging as a major cause of heart attacks and stroke, as deadly as high blood pressure or cholesterol. Full article here.

TARGET Study Finds Major Differences between Childhood and Adult AML

Originally Published: 01/30/2018
An NCI-funded study has found that, at the genetic level, acute myeloid leukemia (AML) differs greatly between younger and older patients.

Therapeutic Vaccine Combination May Help Patients with Myelodysplastic Syndrome

Originally Published: 01/30/2018
It may be possible to vaccinate against induced NY-ESO-1 expression to produce an antigen-specific immune response in patients with high-risk myelodysplastic syndrome (MDS), according to a study by researchers at Roswell Park Comprehensive Cancer Center. They have found a new immunotherapy approach that may significantly benefit high-risk MDS patients who have limited options.

Monitoring For AML Remissions: Are We Measuring Properly?

Originally Published: 01/18/2018
When it comes to monitoring patients previously treated for acute myeloid leukemia (AML), determining who is in remission is still an imperfect process, according to Richard M. Stone, M.D. Full article here.